|
|
News Breaks
|
February 3, 2012
|
| 12:30 EDT |  | JNJ |
| theflyonthewall.com: | Johnson & Johnson sued in China over alleged price fixing, Shanghai Daily says | | Johnson & Johnson (JNJ) has been accused of price fixing and violating Chinese law by one of its Chinese distributors, and the issue went before a Shanghai court yesterday, according to Shanghai Daily. The distributor, which claims that J&J illegally set a minimum resale price for its suturing products,is seeking compensation of about $2.37M the publication added. Reference Link :theflyonthewall.com |
|
|
News For JNJ From The Last 14 Days Check below for free stories on JNJ the last two weeks.
There are 12 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 25, 2012
|
| 11:13 EDT | | JNJ |
| theflyonthewall.com: | Chairman: Elan may get offer if Alzheimer drug data positive, Reuters says | | Elan's (ELN) chairman Bob Ingram said yesterday it was possible that the company could receive a takeover offer if data on an bapineuzumab, an experimental Alzheimer's drug it has a 25% economic interest in, is positive, reported Reuters. "If an offer comes in we can't ignore it, but it is not our strategy to sell the company," Ingram says. The drug is being developed by Pfizer (PFE) and Johnson and Johnson (JNJ), Reuters noted. Reference Link :theflyonthewall.com |
| | 09:31 EDT |  | JNJ |
|
|
May 24, 2012
|
| 07:13 EDT |  | JNJ |
| theflyonthewall.com: | J&J's Xarelto likely delayed 3-12 months, not dead, says Leerink | | Leerink believes the FDA panel vote against approval of Johnson & Johnson's (JNJ) and Bayer's (BAYRY) Xarelto for the prevention of CV events in patients with a recent acute coronary syndrome will likely delay approval by 3-12 months, not kill the drug for this indication. The firm believes Bristol-Myers' (BMY) and Pfizer's (PFE) Eliquis could benefit slightly from a Xarelto delay. :theflyonthewall.com |
| | 06:50 EDT |  | JNJ |
| | 06:06 EDT |  | JNJ |
| | 06:05 EDT | | JNJ |
|
|
May 23, 2012
|
| 16:21 EDT | | JNJ |
| | 07:10 EDT | | JNJ |
| theflyonthewall.com: | FTC, Senate probing blocking of generic drug companies, Washington Post says | | The Federal Trade Commission and the U.S. Senate are investigating whether pharmaceutical companies are using a loophole to prevent generic drug makers from obtaining samples of brand name drugs, according to The Washington Post. The FDA requires generic drug makers to test a sample of brand name versions in order to get a generic drug approved, the newspaper notes. Reference Link :theflyonthewall.com |
|
|
May 21, 2012
|
| 14:38 EDT | | JNJ |
| theflyonthewall.com: | Janssen presents data from Phase 3 study of anti-TNF Simponi | | Janssen Research & Development said that new study findings show that subcutaneous induction regimens of the anti-tumor necrosis factor-alpha therapy Simponi induced clinical response in a majority of patients with moderately to severely active ulcerative colitis who had previously failed or were intolerant to conventional agents. Investigators presented data from the Janssen-sponsored Phase 3 study at Digestive Disease Week during a late breaker session and reported that more than 50% of patients in each of two Simponi dosing groups achieved clinical response at week 6, the primary endpoint of the study, which was significantly more than those in clinical response after receiving placebo. Treatment with Simponi also resulted in significant induction of clinical remission and mucosal healing and improvement in health-related quality of life measures at week 6 compared with placebo, Janssen said. :theflyonthewall.com |
| | 09:43 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson management to meet with JPMorgan | | Meeting to be held in Boston on May 24 hosted by JP Morgan. :theflyonthewall.com |
|
|
May 15, 2012
|
| 09:37 EDT | | JNJ |
|
|
May 14, 2012
|
| 06:42 EDT | | JNJ |
|
|
|
|
|
Subscribe for More Information